

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 22, 2013

CORONADO BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-35366
(Commission
File Number)

20-5157386
(IRS Employer
Identification No.)

24 New England Executive Park, Burlington, MA
(Address of Principal Executive Offices)

01803
(Zip Code)

Registrant's Telephone Number, Including Area Code: (781) 652-4500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On April 22, 2013, our President, Dr. Bobby W. Sandage, Jr., resigned from his position as President and as a director of our company, effective immediately. Pursuant to an amended employment agreement, Dr. Sandage's earlier reported change of status from Chief Executive Officer to President entitled him to terminate his employment agreement for "good reason" (as defined in his employment agreement) at any time prior to June 28, 2013. With his resignation, we are obligated to pay Dr. Sandage his annual salary of \$406,850 and his COBRA premiums for a twelve-month period. In addition, an aggregate of 100,000 options automatically vested in full, and he will have two years from his resignation to exercise these and all other previously vested options.

A copy of the press release regarding the above matters is attached hereto as Exhibit 99.1. The foregoing description of our obligations under Dr. Sandage's amended employment agreement is qualified in its entirety by reference to that agreement, a copy of which was filed as an exhibit to our Annual Report on Form 10-K for the year ended December 31, 2012.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated April 24, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORONADO BIOSCIENCES, INC.

Date: April 24, 2013

/s/ Dale Ritter

Name: Dale Ritter

Title: Senior Vice President, Finance



CORONADO BIOSCIENCES ANNOUNCES DEPARTURE OF DR. BOBBY W. SANDAGE, JR.

Burlington, MA – April 24, 2013 – Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the departure of Dr. Bobby W. Sandage, Jr., President and Director of the Company, to pursue other interests. Dr. Sandage served as President and Chief Executive Officer and Director from March 2011 through December 2012, and as President and Director from January 2013 until his departure.

“We thank Bobby for his outstanding leadership and tireless efforts in helping to bring Coronado to where we are today,” said Dr. Harlan F. Weisman, Coronado’s Chairman and CEO. “Bobby was responsible for building the initial management team, securing several rounds of financing, taking the company public and successfully advancing Coronado’s exciting clinical stage pipeline. We wish him much success in his future endeavors. Moving forward, we anticipate results from TSO’s two phase 2 trials in Crohn’s disease in the second half of this year, and potentially data from investigator-initiated autism and psoriasis studies, and we remain committed to continuing our momentum throughout 2013 and thereafter.”

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company’s two principal pharmaceutical product candidates in clinical development are: TSO (*Trichuris suis* ova or CNDO-201), a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit www.coronadobiosciences.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the company’s product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated risks relating to the results of research and development activities, uncertainties relating to preclinical and clinical testing, our ability to attract, integrate and retain key personnel, financing and strategic agreements and relationships, the early stage of products under development, our need for substantial additional funds, government regulation, patent and intellectual property matters; our dependence on third party suppliers and competition, as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Lucy Lu, MD, Executive Vice President & Chief Financial Officer
Coronado Biosciences, Inc.
781-652-4525; lr@coronadobio.com

Marcy Nanus, Vice President
The Trout Group, LLC.
646-378-2927; mnanus@troutgroup.com

Susan Forman
Dian Griesel Inc.
212-825-3210; susan@dgi-comm.com